Ph.D., Senior Research Advisor, Eli Lilly
Dr. Driscoll is currently a Senior Research Advisor and Group Leader in the Oncology Research division at Eli Lilly. Dr. Driscoll joined Eli Lilly In 2008 and is based in the New York laboratories of Lilly where her current efforts are focused on immune oncology targets and combinations with mechanistic analysis of biological activity. Driscoll is responsible for oversight and development of Lilly’s TGFβ platform, various immune checkpoint antagonists, and myeloid immuno-biology. These programs include both small molecules and biologics, and have advanced to various phases of clinical development. Driscoll obtained her Ph.D. in 2007 in microbiology and immunology where she studied viral mechanisms of oncogenesis. Driscoll further completed postdoctoral training in cancer vaccine development prior to joining Lilly.